TransMedics to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum
TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplantation technology, will host one-on-one meetings at the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum on November 18, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplantation technology, will host one-on-one meetings at the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum on November 18, 2021. The company is dedicated to improving organ transplant therapy for patients with end-stage lung, heart, and liver failure. TransMedics specializes in portable extracorporeal warm perfusion and assessment of donor organs, aiming to enhance organ quality and increase the utilization of donor organs.
Details
News Market Reaction – TMDX
The recorded move for TMDX in the trading session of this news was +1.25%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANDOVER, Mass., Nov. 4, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum on Thursday, November 18, 2021.
For more information on the company, please visit https://investors.transmedics.com/.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
631-807-1986
Investors@transmedics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-participate-in-the-canaccord-genuity-virtual-medtech-diagnostics-and-digital-health--services-forum-301415984.html
SOURCE TransMedics Group, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.